Sonoma Pharmaceuticals (Formerly Known As Oculus Innovative Sciences, Inc.), Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the expansion of its Microcyn® Negative-Pressure Wound Therapy (NPWT) Solution products in the United States.
Microcyn Negative-Pressure Wound Therapy Solution, an innovation in advanced wound care, is now available in convenient sizes of 250mL, 450mL, and 990mL. Designed to meet the diverse needs of healthcare professionals and patients, Microcyn NPWT Solution is a cutting-edge solution that provides effective cleaning and irrigation for wounds with precision and reliability. Microcyn NPWT Solution complements a wide array of negative-pressure therapies. Sonoma's solution delivers optimal wound cleansing and management, promoting faster healing and improved patient outcomes. It does not contain antibiotics, and as a result, it does not promote antibiotic resistance and helps reduce odor by removing necrotic tissue.
Sonoma will showcase this expanded product line at CPHI Japan in Tokyo April 17-19, 2024, at booth 5K-03. Sonoma will also showcase Microcyn NPWT Solution at the Symposium on Advanced Wound Care (SAWC) Spring Conference in Orlando, Florida, May 14-18, 2024 at booth 1102. To set up a meeting at either conference, please contact busdev@sonomapharma.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.